 |
Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?
Schaefer EJ, Asztalos BF.
Curr Opin Cardiol. 2007 Jul;22(4):373-8.
|
|
Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
Asztalos BF, Le Maulf F, Dallal GE, Stein E, Jones PH, Horvath KV, McTaggart F, Schaefer EJ.
Am J Cardiol. 2007 Mar 1;99(5):681-5. Epub 2007 Jan 4
|
|
Should we target HDL-cholesterol to reduce coronary heart disease risk?
Schaefer EJ, Asztalos BF.
Nat Clin Pract Endocrinol Metab. 2006 Jul;2(7):358-9. Review.
|
|
Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.
Schaefer EJ, Asztalos BF
Curr Opin Lipidol. 2006 Aug;17(4):394-8
|
|
Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial.
Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, Robins SJ, Schaefer EJ.
Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2185-91. Epub 2005 Aug 25.
|
|
High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study.
Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ.
Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):2181-7. Epub 2004 Sep 23.
|
|
Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.
Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, Brown GB, Schaefer EJ.
Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):847-52. Epub 2003 Mar 13.
|
|
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ.
Atherosclerosis. 2002 Oct;164(2):361-9.
|
|
Lipoproteins, nutrition, and heart disease.
Schaefer EJ.
Am J Clin Nutr. 2002 Feb;75(2):191-212
|
